investors

Press Releases

DateTitle and SummaryView
August 21, 2015
LOS ANGELES , Aug. 21, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today issued the following letter to shareholders. To Our Shareholders: As we work toward building a leading cancer immunotherapy company, the management and board of directors of
ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial
August 13, 2015
LOS ANGELES , Aug. 13, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced today that it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer
ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma
August 6, 2015
ICT-107 Phase 3 Registration Trial to Begin Late Third Quarter or Early Fourth Quarter 2015; Stem-to-T-cell Program Advancing
ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results
July 23, 2015
LOS ANGELES , July 23, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report financial results for the second quarter 2015 on Thursday, August 6, 2015 . The Company also plans to hold a conference call and webcast on
ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015
July 6, 2015
LOS ANGELES , July 6, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma.
ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma
June 29, 2015
LOS ANGELES , June 29, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the Cantor Fitzgerald Inaugural Healthcare
ImmunoCellular Therapeutics to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8th
June 22, 2015
LOS ANGELES , June 22, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of
ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial
June 15, 2015
LOS ANGELES , June 15, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced the selection of PCT, LLC , a subsidiary of Caladrius Biosciences, Inc. ("Caladrius") (NASDAQ:CLBS), as the US manufacturer for ImmunoCellular's ICT-107 phase 3
ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial
May 19, 2015
LOS ANGELES , May 19, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the Marcum MicroCap Conference on Thursday,
ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 28th
May 11, 2015
Phase 3 Registration Trial for ICT-107 to Initiate in Second Half of 2015; Financial Results Conference Call to be Held on May 12, 2015
ImmunoCellular Therapeutics Announces First Quarter 2015 Financial Results
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved